-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs raised Colon Pharmaceuticals's rating to buy, with a target price of 47 yuan.

智通財經·04/20/2026 00:01:01
語音播報
Goldman Sachs raised Colon Pharmaceuticals's rating to buy, with a target price of 47 yuan.